BX Commercial Mortgage Trust 2026-585K wins final Fitch ratings for $915 million Cambridge loan
A new commercial mortgage securitization tied to a fully leased life sciences property in Cambridge is moving ahead with final ratings on its senior classes. The transaction is backed by a $915.0 million floating-rate loan on 585 Kendall, a newly delivered Kendall Square asset leased to Takeda Pharmaceuticals U.S.A., Inc. as its U.S. headquarters and a key global R&D center.
Highlights
- BX Commercial Mortgage Trust 2026-585K closed a $915.0 million floating-rate loan with class A notes rated 'AAAsf' and Stable Outlook by Fitch.
- The loan refinances $490.1 million debt, returns $280.1 million equity, and funds $129.5 million landlord obligations for a 598,502-sq.-ft. Cambridge life science asset.
- Takeda Pharmaceuticals fully leases the property under a 15-year triple-net lease, with $500.0 million total lab buildout investments and Fitch valuing the asset at $1.16 billion.
Final ratings and transaction structure
As reported by Fitch Ratings, BX Commercial Mortgage Trust 2026-585K has received final ratings and Rating Outlooks on its commercial mortgage pass-through certificates, with the class A notes rated 'AAAsf', class B rated 'AA-sf' and class C rated 'A-sf', all with Stable Outlooks.Fitch does not rate class D or the RR interest classes. The certificates represent beneficial ownership in an interest-only, two-year, floating-rate mortgage loan with three one-year extension options and an aggregate outstanding principal balance of $915.0 million.
Loan proceeds are set to refinance $490.1 million of existing debt, return $280.1 million of equity, fund $129.5 million of landlord obligations and cover $15.3 million in closing costs. The sponsor is indirectly owned and controlled by affiliates of BioMed Realty, L.P., a Blackstone portfolio company, while the loan is expected to be co-originated by Wells Fargo Bank, N.A., Citi Real Estate Funding Inc., Goldman Sachs Bank USA, JPMorgan Chase Bank, N.A. and Royal Bank of Canada.
KeyBank N.A. is serving as servicer and special servicer, and Computershare Trust Company, N.A. is acting as trustee and certificate administrator. The certificates follow a sequential-pay structure, except in certain prepayment cases tied to assumptions and recapitalizations.
Cambridge asset quality and credit support
The loan is secured by the fee interest in 585 Kendall, a newly delivered 16-story Class A life science lab and office condominium unit spanning about 598,502 square feet in the Kendall Square submarket of Cambridge, Massachusetts. Fitch says the property is 100% leased to Takeda Pharmaceuticals U.S.A., Inc. under a 15-year triple-net lease that expires in June 2041, around 10 years beyond the loan's fully extended five-year term, with a guarantee from Takeda Pharmaceutical Company Limited.Fitch estimates stressed net cash flow at $81.2 million, 19.2% below the issuer's $100.4 million figure, and applies a 7.00% capitalization rate to derive a value of about $1.16 billion. On that basis, the agency says the mortgage loan carries a stressed debt service coverage ratio of 1.11x, a loan-to-value ratio of 78.9% and a debt yield of 8.9%.
The agency also points to substantial tenant and sponsor investment in the property. BioMed is providing about $150.0 million in tenant improvement allowance, while Takeda is expected to invest up to another $350.0 million, bringing total tenant improvements to roughly $500.0 million for specialized laboratory buildout across multiple floors.
Fitch says the asset benefits from institutional sponsorship and strong building specifications, including LEED Platinum design standards and WELL pre-certification. The property has received a Fitch quality grade of 'A-', supporting the credit profile of a transaction concentrated in the U.S. life sciences real estate market.
Our earlier coverage of Fitch’s rating on Hainan Rubber’s proposed subordinated perpetual sustainable securities explained how the agency assessed the notes’ lower ranking in the capital structure and the issuer’s ability to defer coupons. We also outlined Fitch’s view of the group’s leverage and liquidity profile, including the support assumptions tied to its government-related ownership and access to funding.